GRC on Radionuclide Theranostics for the Management of Cancer
21 - 26 Jun 2020
Safe and effective delivery of targeted radiopharmaceuticals requires delineation of the best target for each malignant disease as well as delivering a safe dose in the context of an overall treatment plan precisely developed for a specific patient. Solution: Radionuclide Theranostics, exerting its cytotoxic action through direct DNA strand breaks and bystander effects on tumor and supporting stroma, has the potential to achieve tumor control with minimal toxicity, improved quality of life and prolonged survival.
The goals of this multi-disciplinary Gordon Research Conference will be: 1) to identify new molecular targets and targeting vectors for specific malignancies such as prostate, breast and lung cancer, taking advantage of recent discoveries in cancer genetics, stem cell biology, tumor cell migration, regulation of gene expression, and medical uses of radionuclides; 2) to optimize therapeutic benefit based on understanding of radionuclide risks to normal tissues; and 3) to explore how radiopharmaceutical imaging and therapy can be combined with targeted biologicals to cure resistant malignancies while improving quality of life.
Meeting these goals will require cooperation and collaboration of nuclear medicine physicists and physicians; endocrinologists, oncologists, gastroenterologists, and surgeons; biologists, chemists, and pharmacologists all working together with industry and philanthropic partners to translate this science into medicine.